» Articles » PMID: 38895239

Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations

Overview
Journal bioRxiv
Date 2024 Jun 19
PMID 38895239
Authors
Affiliations
Soon will be listed here.
Abstract

Post-Acute Sequelae of COVID-19 (PASC) encompasses persistent neurological symptoms, including olfactory and autonomic dysfunction. Here, we report chronic neurological dysfunction in mice infected with a virulent mouse-adapted SARS-CoV-2 that does not infect the brain. Long after recovery from nasal infection, we observed loss of tyrosine hydroxylase (TH) expression in olfactory bulb glomeruli and neurotransmitter levels in the substantia nigra (SN) persisted. Vulnerability of dopaminergic neurons in these brain areas was accompanied by increased levels of proinflammatory cytokines and neurobehavioral changes. RNAseq analysis unveiled persistent microglia activation, as found in human neurodegenerative diseases. Early treatment with antivirals (nirmatrelvir and molnupiravir) reduced virus titers and lung inflammation but failed to prevent neurological abnormalities, as observed in patients. Together these results show that chronic deficiencies in neuronal function in SARS-CoV-2-infected mice are not directly linked to ongoing olfactory epithelium dysfunction. Rather, they bear similarity with neurodegenerative disease, the vulnerability of which is exacerbated by chronic inflammation.

References
1.
Verma A, Zheng J, Meyerholz D, Perlman S . SARS-CoV-2 infection of sustentacular cells disrupts olfactory signaling pathways. JCI Insight. 2022; 7(24). PMC: 9869979. DOI: 10.1172/jci.insight.160277. View

2.
Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P . SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022; 604(7907):697-707. PMC: 9046077. DOI: 10.1038/s41586-022-04569-5. View

3.
Eden A, Grahn A, Bremell D, Aghvanyan A, Bathala P, Fuchs D . Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms. JAMA Netw Open. 2022; 5(5):e2213253. PMC: 9127556. DOI: 10.1001/jamanetworkopen.2022.13253. View

4.
Tata A, Velluto L, DAngelo C, Reale M . Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?. CNS Neurol Disord Drug Targets. 2014; 13(7):1294-303. DOI: 10.2174/1871527313666140917121132. View

5.
Wilke V, Sulyok M, Stefanou M, Richter V, Bender B, Ernemann U . Delirium in hospitalized COVID-19 patients: Predictors and implications for patient outcome. PLoS One. 2022; 17(12):e0278214. PMC: 9778494. DOI: 10.1371/journal.pone.0278214. View